A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


November 14, 2013

Rates of Failure in HIV Drugs Vary Widely in Poorer Nations

There is a vast range in outcomes of success at suppressing HIV with antiretroviral (ARV) treatment among people taking the drugs in resource-limited nations, aidsmap reports. Publishing their findings in Clinical Infectious Diseases, an international group of researchers conducted a cross-sectional study between Burkina Faso, Cameroon, Côte d’Ivoire, Senegal, Togo, Thailand and Vietnam in order to determine the rate of virologic failure and drug resistance mutations (DRMs) among HIV-positive people receiving treatment under the World Health Organization’s protocol for both delivery and monitoring of treatment.

Between 2009 and 2011, the investigators recruited 2,060 adults who were attending treatment centers 10 to 14 months after beginning ARVs (called the M12 group) and 1,875 adults in the 22 to 26 month range (the M24 group).

The average rate of virologic failure was 11.1 percent for the M12 group and 12.4 percent for the M24 group. The respective rates of drug-resistant virus among those in the groups who had virologic failure were 71 percent and 86.1 percent for the M12 and M24 group. Virologic failure rates ranged between 2.9 percent and 20.6 percent in the M12 group and 3.7 percent to 26 percent in the M24 group. For the most part, DRMs were linked to ARV regimens, but several of the participants racked up DRMs to drugs they had not received.

The study authors concluded that proper management of ARV programs is “critical to improve treatment outcomes in resource-limited countries.”

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: HIV, virologic failure, suppressed viral load, aidsmap, Burkina Faso, Cameroon, Côte d’Ivoire, Senegal, Togo, Thailand, Vietnam, drug resistance mutations, DRM.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (1 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.